Wendy Chen, PA
Authored Items
Maria Badillo, MSN, RN, Diana Nava, RN, Maria de la Rosa, Wendy Chen, PA, Maria Guerrero, DNP, MS, RN, Michael Wang, MD
October 25, 2019 | November 2019 Vol 10, No 11
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor, approved for use in adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL), an aggressive B-cell malignancy.
Last modified: November 6, 2019